These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15304171)

  • 21. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
    Wheatley K; Gray R
    Lancet; 2003 Oct; 362(9392):1333; author reply 1334. PubMed ID: 14575997
    [No Abstract]   [Full Text] [Related]  

  • 24. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
    Darcy KM; Brady WE; McBroom JW; Bell JG; Young RC; McGuire WP; Linnoila RI; Hendricks D; Bonome T; Farley JH;
    Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Good manners for the pharmaceutical industry.
    Gore M; A'Hern R; Swenerton K
    Lancet; 1997 Aug; 350(9074):370. PubMed ID: 9251668
    [No Abstract]   [Full Text] [Related]  

  • 27. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
    Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapy for ovarian cancer.
    Neijt JP
    N Engl J Med; 1996 Jan; 334(1):50-1. PubMed ID: 7494573
    [No Abstract]   [Full Text] [Related]  

  • 29. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?
    Sugiyama T
    Int J Clin Oncol; 2006 Jun; 11(3):163. PubMed ID: 16850120
    [No Abstract]   [Full Text] [Related]  

  • 30. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.
    Reed E; Kohn EC; Sarosy G; Dabholkar M; Davis P; Jacob J; Maher M
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):90-6. PubMed ID: 7541159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy for ovarian cancer.
    Lacave AJ; Peláez I; Palacio I
    N Engl J Med; 1996 May; 334(19):1269-70. PubMed ID: 8606731
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
    Rustin GJ; Timmers P; Nelstrop A; Shreeves G; Bentzen SM; Baron B; Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Eisenhauer E
    J Clin Oncol; 2006 Jan; 24(1):45-51. PubMed ID: 16382112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 36. [New regimens for the treatment of gynecologic cancers].
    Sugiyama T; Ushijima K; Kamura T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
    Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
    Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
    [No Abstract]   [Full Text] [Related]  

  • 40. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.